List of Contract Manufacturing Companies in Denmark - 2

At Fertin Pharma we specialize in the development and manufacturing of oral and intra-oral dosage formats. Our mission – Supporting Healthier Living – is carried out through our continuous desire to create the most innovative and consumer-friendly consumer healthcare products in the market. With an innovative and global profile, we engage in successful partnerships with leading pharmaceutical & nutraceutical companies. Supported by an experienced Research & Development team, extensive expertise in sensory optimisation and advanced manufacturing facilities, we support our customers from product formulation development to testing, manufacturing and regulatory compliance in order to ensure a smooth market launch. With a history dating all the way back to 1915, we have accumulated vast expertise and know-how within the field of chewing gum and other delivery formats. This knowledge is the foundation of our company, and it supports our vision of being the world’s leading supplier of pleasurable and convenient oral delivery systems. Fertin is also focused on the advancement in the science of Nicotine. For this reason we have started the Nicotine Science Center, which contributes with scientific insight into nicotine and its delivery. Visit the Nicotine Science Center Website. Copy this link into your browser: www.nicotinesciencecenter.com

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/